C Röcken1, J Licht, A Roessner, S Carl-McGrath. 1. Department of Pathology, Otto-von-Guericke-University, Leipziger Str. 44, D-39120 Magdeburg, Germany. christoph.roecken@medizin.uni-magdeburg.de
Abstract
BACKGROUND: Aminopeptidase N (CD13) is expressed in normal and neoplastic liver tissue, where it exhibits a characteristic canalicular pattern (CD13(can)), similar to that seen for CD10 and when antibodies crossreact with biliary glycoprotein I (p-CEA). AIM: To compare the putative diagnostic use of CD13(can) in differentiating between hepatocellular (HCC) and non-hepatocellular carcinomas metastatic to the liver (non-HCC). METHODS: A retrospective study comparing 53 HCC specimens with 32 non-HCC specimens. Immunostaining was performed with HepPar1 and antibodies directed against CD10, CD13, p-CEA, and alpha fetoprotein (AFP). RESULTS: In the HCC group, a canalicular staining pattern was found for CD13, p-CEA, and CD10 in 51, 43, and 33 specimens, respectively. HepPar1 was positive in 29 and AFP in 17 HCC specimens. In the non-HCC group, canalicular immunostaining for CD10 and p-CEA was confined to non-neoplastic liver tissue. One poorly differentiated cholangiocarcinoma showed apical expression of CD13, resembling to some extent CD13(can). Sensitivity and specificity were 96.2% and 97.0%, respectively, for CD13(can), 81.1% and 100% for p-CEA(can), 62.3% and 100%, for CD10(can), 54.7% and 99.9% for HepPar1, and 32.1% and 100% for AFP. CONCLUSIONS: These results show that CD13(can) is more sensitive in differentiating between HCC and non-HCC than CD10(can), p-CEA(can), HepPar1, and AFP.
BACKGROUND:Aminopeptidase N (CD13) is expressed in normal and neoplastic liver tissue, where it exhibits a characteristic canalicular pattern (CD13(can)), similar to that seen for CD10 and when antibodies crossreact with biliary glycoprotein I (p-CEA). AIM: To compare the putative diagnostic use of CD13(can) in differentiating between hepatocellular (HCC) and non-hepatocellular carcinomas metastatic to the liver (non-HCC). METHODS: A retrospective study comparing 53 HCC specimens with 32 non-HCC specimens. Immunostaining was performed with HepPar1 and antibodies directed against CD10, CD13, p-CEA, and alpha fetoprotein (AFP). RESULTS: In the HCC group, a canalicular staining pattern was found for CD13, p-CEA, and CD10 in 51, 43, and 33 specimens, respectively. HepPar1 was positive in 29 and AFP in 17 HCC specimens. In the non-HCC group, canalicular immunostaining for CD10 and p-CEA was confined to non-neoplastic liver tissue. One poorly differentiated cholangiocarcinoma showed apical expression of CD13, resembling to some extent CD13(can). Sensitivity and specificity were 96.2% and 97.0%, respectively, for CD13(can), 81.1% and 100% for p-CEA(can), 62.3% and 100%, for CD10(can), 54.7% and 99.9% for HepPar1, and 32.1% and 100% for AFP. CONCLUSIONS: These results show that CD13(can) is more sensitive in differentiating between HCC and non-HCC than CD10(can), p-CEA(can), HepPar1, and AFP.
Authors: T Tokuhara; M Adachi; H Hashida; H Ishida; T Taki; M Higashiyama; K Kodama; S Tachibana; S Sasaki; M Miyake Journal: Jpn J Thorac Cardiovasc Surg Date: 2001-08
Authors: Liliana Guzman-Rojas; Roberto Rangel; Ahmad Salameh; Julianna K Edwards; Eleonora Dondossola; Yun-Gon Kim; Alan Saghatelian; Ricardo J Giordano; Mikhail G Kolonin; Fernanda I Staquicini; Erkki Koivunen; Richard L Sidman; Wadih Arap; Renata Pasqualini Journal: Proc Natl Acad Sci U S A Date: 2012-01-17 Impact factor: 11.205
Authors: D K Mathias; J L Plieskatt; J S Armistead; J M Bethony; K B Abdul-Majid; A McMillan; E Angov; M J Aryee; B Zhan; P Gillespie; B Keegan; A R Jariwala; W Rezende; M E Bottazzi; D G Scorpio; P J Hotez; R R Dinglasan Journal: Infect Immun Date: 2012-02-06 Impact factor: 3.441
Authors: L Wang; J Wang; X Zhou; J Li; Y Shi; Z Han; X Wang; S Li; Z Yang; R Wang; D Fan; Y Han Journal: Eur J Histochem Date: 2012-06-29 Impact factor: 3.188
Authors: K D Sørensen; M O Abildgaard; C Haldrup; B P Ulhøi; H Kristensen; S Strand; C Parker; S Høyer; M Borre; T F Ørntoft Journal: Br J Cancer Date: 2013-01-15 Impact factor: 7.640